GlassScriptPhysician profile
Ada R Ene
NPI 1760616916
$2,188.97
in general payments reported to CMS, 2019-2025
19 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.80 · 2023: $594 · 2024: $1,378 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $604.88 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $212.00 | 2024 | Voquezna |
| Lilly USA, LLC | $207.15 | 2023-2024 | Omvoh, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $205.27 | 2023-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.64 | 2023-2024 | Trulance |
| Napo Pharmaceuticals INC | $135.00 | 2025 | Mytesi |
| Vivus LLC | $130.40 | 2023-2024 | Qsymia |
| Novo Nordisk INC | $107.83 | 2023 | Wegovy, Saxenda |
| Redhill Biopharma INC. | $75.60 | 2023-2024 | Talicia |
| Ardelyx, INC. | $69.83 | 2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $59.56 | 2024 | |
| Merck Sharp & Dohme LLC | $51.98 | 2024 | Dificid |
| Blueprint Medicines Corporation | $37.63 | 2023 | |
| Genzyme Corporation | $34.29 | 2024 | |
| Gilead Sciences, INC. | $27.86 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23.57 | 2024 | Injectafer |
| Glaxosmithkline, LLC. | $22.16 | 2020 | |
| Phadia US INC. | $15.68 | 2025 | Immunocap |
| Esperion Therapeutics, INC. | $15.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ada Ene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.